Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
0.00%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 696 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
TuHURA Biosciences, Inc.
Market Cap
$121.63M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$122.13M
Net Profit Margin
-2258.89%
TTM Avg
-4695.34%
3Y Avg
-8719.58%
5Y Avg
-5863.11%
Market Cap
$123.26M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$118.99M
Net Profit Margin
-586.74%
TTM Avg
-215.13%
3Y Avg
-125.58%
5Y Avg
-83.72%
Market Cap
$125.34M
Net Profit Margin
-691.81%
TTM Avg
-1168.24%
3Y Avg
-584.12%
5Y Avg
-389.41%
Market Cap
$117.53M
Net Profit Margin
-1030.42%
TTM Avg
-1409.68%
3Y Avg
-958.30%
5Y Avg
-801.33%
Market Cap
$116.89M
Net Profit Margin
-2955.63%
TTM Avg
-2231.78%
3Y Avg
-3480.44%
5Y Avg
-3216.57%
Market Cap
$116.34M
Net Profit Margin
-175.78%
TTM Avg
-311.79%
3Y Avg
-369.50%
5Y Avg
-4193.27%
Market Cap
$116.59M
Net Profit Margin
-422412.50%
TTM Avg
-387587.50%
3Y Avg
-197966.84%
5Y Avg
-131977.89%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $121.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cibus, Inc. (CBUS)vs › | $122.13M | -2258.89% | -4695.34% | -8719.58% | -5863.11% |
| enGene Holdings Inc. (ENGN)vs › | $123.26M | 0.00% | 0.00% | 0.00% | 0.00% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.99M | -586.74% | -215.13% | -125.58% | -83.72% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.34M | -691.81% | -1168.24% | -584.12% | -389.41% |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | -1030.42% | -1409.68% | -958.30% | -801.33% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.89M | -2955.63% | -2231.78% | -3480.44% | -3216.57% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.34M | -175.78% | -311.79% | -369.50% | -4193.27% |
| Genelux Corporation (GNLX)vs › | $116.59M | -422412.50% | -387587.50% | -197966.84% | -131977.89% |
| Coya Therapeutics, Inc. (COYA)vs › | $116.35M | -270.22% | -342.92% | -204.73% | -136.49% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
